The evolution of ovarian carcinoma subclassification

M Köbel, EY Kang - Cancers, 2022 - mdpi.com
Simple Summary Historically, cancers presenting with their main tumor mass in the ovary
have been classified as ovarian carcinomas (a concise term for epithelial ovarian cancer) …

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

EY Kang, A Weir, NS Meagher, K Farrington… - Cancer, 2023 - Wiley Online Library
Abstract Background Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic
target in tubo‐ovarian high‐grade serous carcinoma (HGSC). Smaller studies have revealed …

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

FAM Saner, K Takahashi, T Budden… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: The purpose of this study was to evaluate RB1 expression and survival across
ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) …

Immunohistochemical comparison of Ki-67 and MCM-3 in odontogenic cysts: An observational study

R Bhola, A Narwal, M Kamboj… - … & Molecular Morphology, 2024 - journals.lww.com
Odontogenic cysts are a diverse group of pathologic entities with different proliferation
potential, leading to variations in their biological behavior. One of the most cited proliferation …

The prognostic and immunological role of MCM3 in pan-cancer and validation of prognosis in a clinical lower-grade glioma cohort

QR Huang, Q Jiang, JY Tan, RB Nong, J Yan… - Frontiers in …, 2024 - frontiersin.org
Background: Previous studies have shown that MCM3 plays a key role in initiating DNA
replication. However, the mechanism of MCM3 function in most cancers is still unknown. The …

Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas

M Köbel, RZ Yang, EY Kang, Z Al-Shamma… - Gynecologic …, 2023 - Elsevier
Objective Inhibition of the MAPK pathway by MEK inhibitors (MEKi) is currently a therapeutic
standard in several cancer types, including ovarian low-grade serous carcinoma (LGSC). A …

Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis

W Xie, L Zhang, J Shen, F Lai, W Han, X Liu - BMC cancer, 2024 - Springer
Objective We aimed to screen novel gene signatures for ovarian cancer (OC) and explore
the role of biomarkers in OC via regulating pyroptosis using bioinformatics analysis …

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis …

A Weir, EY Kang, NS Meagher, GS Nelson… - British journal of …, 2023 - nature.com
Background Recently, we showed a> 60% difference in 5-year survival for patients with tubo-
ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA …

Proteogenomic Characterization Reveals Therapeutic Opportunities Related to Mitochondrial Function in Melanoma

J Gil, Y Kim, V Doma, U Çakır, M Kuras, LH Betancourt… - bioRxiv, 2022 - biorxiv.org
The dynamics of more than 1900 mitochondrial proteins was explored through quantitative
proteomics in 151 melanoma-related tissue samples of both surgical and autopsy origin …

Quantifying Intratumoral Biomarker Heterogeneity in Tubo-ovarian High-grade Serous Carcinoma to Optimize Clinical Translation

A Talhouk, DS Chiu, L Meunier, K Rahimi, C Le Page… - 2024 - researchsquare.com
Intratumoral heterogeneity (ITH) is spatial, phenotypic, or molecular differences within the
same tumor that have important implications for accurate tumor classification and …